{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:18:52Z","timestamp":1792289932622,"version":"4.4.0"},"reference-count":32,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Headaches are a very common condition that most people will experience many times during their lives. This article presents the primary headaches, which are a large group of diseases where the headache is not a symptom of another known disease. Tension-type headache affects approximately 80% of the general population, and the prevalence of migraine is estimated at 10\u201312%. Clinical data and experience to date have demonstrated that botulinum toxin may be an effective prophylactic treatment for chronic headache types. It has been used in neurology for the treatment of dystonia and blepharospasm. Now it has been approved to treat chronic migraine and has been shown to confer significant benefit in refractory cases. Based on clinical experience botulinum toxin has also been tried in other headache disorders. While it is intuitively attractive to think that due to its effect on pain by sensory modulation, there may also be efficacy in its use in chronic tension-type headache and cluster headache, so far, there is little evidence to support this. Botulinum toxin is effective in pain control through its interaction with the SNARE complex, which inhibits the release of neurotransmitters, such as glutamate, substance P and calcitonin gene-related peptide. OnabotulinumtoxinA is effective not only in headache frequency and pain intensity but in other parameters, including quality of life.<\/jats:p>","DOI":"10.3390\/toxins14090619","type":"journal-article","created":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T09:51:09Z","timestamp":1662630669000},"page":"619","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Botulinum Toxin\u2014A Current Place in the Treatment of Chronic Migraine and Other Primary Headaches"],"prefix":"10.3390","volume":"14","author":[{"given":"Katarzyna","family":"K\u0119pczy\u0144ska","sequence":"first","affiliation":[{"name":"Department of Neurology, Medical University of Warsaw, 80 Ceg\u0142owska St., 01-809 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3130-1036","authenticated-orcid":false,"given":"Izabela","family":"Domitrz","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University of Warsaw, 80 Ceg\u0142owska St., 01-809 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,5]]},"reference":[{"key":"ref_1","unstructured":"(2018). Headache Classification Commitee of the International Headache Society, International Classification of Headache Disorders, 3rd edition. Cephalalgia, 38, 1\u2013211."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1177\/0333102421999996","article-title":"The secondary Headaches","volume":"41","author":"Bahra","year":"2021","journal-title":"Cephalalgia"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s10194-016-0699-5","article-title":"GBD 2015: Migraine is the third cause of disability in under 50s","volume":"17","author":"Steiner","year":"2016","journal-title":"J. Headache Pain"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1111\/j.1526-4610.2006.00577.x","article-title":"Modifiable risk factors for migraine progression","volume":"46","author":"Bigal","year":"2006","journal-title":"Headache"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ncl.2019.06.001","article-title":"Migraine: Epidemiology, Burden and Comorbidity","volume":"37","author":"Burch","year":"2019","journal-title":"Neurol. Clin."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1177\/0333102410364676","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PRREMPT 1 trial","volume":"30","author":"Aurora","year":"2010","journal-title":"Cephalalgia"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1177\/0333102410364677","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PRREMPT 2 trial","volume":"30","author":"Diener","year":"2010","journal-title":"Cephalalgia"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Becker, W.J. (2020). Botulinum Toxin in the Treatment of Headache. Toxins, 12.","DOI":"10.3390\/toxins12120803"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1111\/bph.12763","article-title":"Therapeutic use of botulinum toxin in migraine: Mechanisms of action","volume":"171","author":"Ramachandran","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/NDT.S17923","article-title":"Critical analysis of the use of onatobotulinumtoxinA (botulinum toxin type A) in migraine","volume":"8","author":"Robertson","year":"2012","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1055\/s-0038-1673683","article-title":"Migraine and Tension-Type Headache","volume":"38","author":"Kahriman","year":"2018","journal-title":"Semin. Neurol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s10194-016-0621-1","article-title":"The efficiency of botulinum toxin type A for the treatment of masseter muscle pain in patients with temporomandibular joint dysfunction and tension-type headache","volume":"17","author":"Pihut","year":"2016","journal-title":"J. Headache Pain"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/head.12185","article-title":"OnabotulinumtoxinA for the treatment of headache","volume":"53","author":"Ashkenazi","year":"2013","journal-title":"Headache"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1515\/sjpain-2021-0038","article-title":"The efficacy of botulinum toxin A treatment for tension-type or cervivogenic headache: A systematic review and meta-analysis of randomized, placebo-controlled trials","volume":"21","author":"Roland","year":"2021","journal-title":"Scand. J. Pain"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s00115-016-0138-5","article-title":"Botulinum toxin type A in headache treatment: Established and experimental indications","volume":"87","author":"Gaul","year":"2016","journal-title":"Nervenarzt"},{"key":"ref_16","first-page":"27","article-title":"Diagnostic lessons from the spectrum study","volume":"14","author":"Lipton","year":"2002","journal-title":"Neurology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"18006","DOI":"10.1038\/nrdp.2018.6","article-title":"Cluster headache","volume":"1","author":"May","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1474-4422(17)30405-2","article-title":"Diagnosis, pathophysiology, and management of cluster headache","volume":"17","author":"Hoffman","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"129","DOI":"10.11607\/ofph.2444","article-title":"The Efficacy of Botulinum Toxin in Cluster Headache: A Systematic Review","volume":"34","author":"Freund","year":"2020","journal-title":"J. Oral Facial Pain Headache"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1177\/0333102415597891","article-title":"Pilot study of sphenopalatine injection of onabotulinumtoxinA for the treatment of itractable chronic cluster headache","volume":"36","author":"Bratbak","year":"2016","journal-title":"Cephalalgia"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1111\/head.13889","article-title":"Open-Label, Multi-Dose, Pilot Safety Study of Injection of OnabotulinumtoxinA toward the Otic Ganglion for the Treatment of Intractable Chroni Cluster Headache","volume":"60","author":"Crespi","year":"2020","journal-title":"Headache"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1177\/0333102414552532","article-title":"The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results","volume":"35","author":"Adams","year":"2015","journal-title":"Cephalalgia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/bs.pbr.2020.05.013","article-title":"OnabotulinumtoxinA injection in the treatment of chronic migraine","volume":"255","author":"Wang","year":"2020","journal-title":"Prog. Brain Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1001\/jama.2012.505","article-title":"Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: A meta-analysis","volume":"307","author":"Jackson","year":"2012","journal-title":"J. Am. Med. Assoc."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.4065\/80.9.1126","article-title":"Botulinum toxin type A for the prophylactic treatment of chronic daily headache: A randomized, double-blind, placebo-controlled trial","volume":"80","author":"Silberstein","year":"2005","journal-title":"Mayo Clin. Proc."},{"key":"ref_26","first-page":"113","article-title":"Botulinum toxin type-A in the prevention of migraine: A double-blind controlled trial","volume":"78","author":"Vo","year":"2007","journal-title":"Aviat. Space Environ. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/j.1526-4610.2010.01766.x","article-title":"Method of injection of onabotulinumtoxinA for chronic migraine: A safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program","volume":"50","author":"Blumenfeld","year":"2010","journal-title":"Headache"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1526-4610.2005.05068.x","article-title":"Botulinum toxin type a for the prophylaxis of chronic daily headache: Subgroup analysis of patients not receiving other prophylactic medications: A randomized double-blind, placebo-cotrolled study","volume":"45","author":"Dodick","year":"2005","journal-title":"Headache"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.toxicon.2015.09.009","article-title":"The long journey of botulinum neurotoxins into the synapse","volume":"107","author":"Rummel","year":"2015","journal-title":"Toxicon"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1111\/head.13849","article-title":"Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review","volume":"60","author":"Burstein","year":"2020","journal-title":"Headache"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.pneurobio.2014.06.001","article-title":"Botulinum toxin A, brain and pain","volume":"119\u2013120","author":"Matak","year":"2014","journal-title":"Prog. Neurobiol."},{"key":"ref_32","first-page":"1","article-title":"Temporomandibular disorders and neck pain in primary headache patients: A retrospective machine learning study","volume":"29","author":"Ferillo","year":"2022","journal-title":"Acta Odontol. Scand."}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/14\/9\/619\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:23:21Z","timestamp":1760142201000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/14\/9\/619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,5]]},"references-count":32,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["toxins14090619"],"URL":"https:\/\/doi.org\/10.3390\/toxins14090619","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,5]]}}}